Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Conditions
- Metastatic HER2-Negative Breast CarcinomaLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Female Reproductive System NeoplasmRecurrent Ovarian CarcinomaUnresectable HER2-Negative Breast CarcinomaUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
- Interventions
- Procedure: BiopsyDrug: AlpelisibDrug: BinimetinibProcedure: Bone Marrow AspirationProcedure: Biospecimen CollectionProcedure: Bone ScanDrug: IpatasertibProcedure: Computed TomographyProcedure: EchocardiographyDrug: Nilotinib Hydrochloride MonohydrateBiological: PanitumumabProcedure: Magnetic Resonance ImagingDrug: PaclitaxelDrug: SotorasibDrug: OlaparibDrug: FluorouracilProcedure: Mutation Carrier ScreeningDrug: Neratinib MaleateDrug: LeucovorinDrug: FulvestrantProcedure: Positron Emission TomographyDrug: PalbociclibProcedure: Multigated Acquisition ScanDrug: Selumetinib SulfateDrug: Oxaliplatin
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2900
- Registration Number
- NCT05564377
- Locations
- 🇺🇸
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan, United States
🇺🇸Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
🇺🇸Corewell Health Farmington Hills Hospital, Farmington Hills, Michigan, United States
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial
- Conditions
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT05554380
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸OhioHealth Westerville Medical Campus/Westerville Cancer Center, Westerville, Ohio, United States
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT05554341
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Kingman Regional Medical Center, Kingman, Arizona, United States
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05552807
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT05543629
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸Local Institution - 0096, Costa Mesa, California, United States
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
- Conditions
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT05522894
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
- Conditions
- Interventions
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Compass Therapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT05506943
- Locations
- 🇺🇸
Virginia Mason Franciscan Health, Seattle, Washington, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 792
- Registration Number
- NCT05502237
- Locations
- 🇦🇷
Clínica Viedma, Viedma, Argentina
🇦🇹Klinikum Klagenfurt am Woerthersee, Klagenfurt Am Woerthersee, Austria
🇺🇸Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
- Conditions
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 146
- Registration Number
- NCT05498896
- Locations
- 🇬🇧
Barts Health NHS Trust, London, United Kingdom
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- EQRx International, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05493501
- Locations
- 🇺🇸
Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
🇺🇸QCCA - Mission Blood & Cancer, Des Moines, Iowa, United States
🇺🇸Memorial Cancer Institute, Pembroke Pines, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.